文献速递慢性肾脏病肾小球疾病

卡格列净对肾脏、心血管及安全性结局的影响:基于基线白蛋白尿的CREDENCE二次分析

Kidney, Cardiovascular, and Safety Outcomes of Canagliflozin according to Baseline Albuminuria: A CREDENCE Secondary Analysis.
PubMed 文献 · Clin J Am Soc Nephrol · 2021-02-22

CREDENCE二次分析纳入4401例2型糖尿病合并慢性肾脏病患者,按基线尿白蛋白肌酐比(UACR)分层,评估卡格列净的疗效与安全性。结果显示卡格列净在各UACR水平均降低肾脏和心血管事件,相对获益一致,但UACR≥3000 mg/g者绝对肾脏获益最大。

要点

  • 卡格列净在UACR≤1000、>1000~<3000、≥3000 mg/g亚组中相对肾脏获益一致。
  • UACR≥3000 mg/g者绝对肾脏获益最大,每1000例治疗2.6年可预防119例主要复合事件。
  • 卡格列净在严重白蛋白尿患者中安全性良好,肾脏相关不良事件率更低。

核心结论

  • 卡格列净在2型糖尿病合并严重白蛋白尿患者中安全降低肾脏和心血管事件。
  • 相对肾脏获益在各UACR水平一致,UACR≥3000 mg/g者绝对肾脏获益最大。

研究设计与样本

  • CREDENCE随机对照试验的二次分析,纳入4401例2型糖尿病、eGFR 30~<90 ml/min/1.73 m²、UACR>300~5000 mg/g的患者。
  • 按基线UACR分为≤1000 mg/g(n=2348)、>1000~<3000 mg/g(n=1547)、≥3000 mg/g(n=506)三组。
  • 采用Cox比例风险回归分析卡格列净对肾脏、心血管及安全性结局的相对和绝对效应。

主要发现

  • 基线UACR越高,肾脏和心血管事件发生率越高。
  • 卡格列净降低主要复合结局:UACR≤1000 mg/g组HR 0.76(95%CI 0.56~1.04),>1000~<3000 mg/g组HR 0.72(95%CI 0.56~0.93),≥3000 mg/g组HR 0.63(95%CI 0.47~0.84),异质性P=0.55。
  • 每1000例治疗2.6年预防的主要复合事件数:UACR≤1000、>1000~<3000、≥3000 mg/g组分别为17(95%CI 3~38)、45(95%CI 9~81)、119(95%CI 35~202),异质性P=0.02。
  • 卡格列净组肾脏相关不良事件率更低,且UACR越高相对降低幅度越大。

临床怎么用

  • 对于2型糖尿病合并慢性肾脏病及严重白蛋白尿(UACR≥3000 mg/g)患者,卡格列净可带来显著的绝对肾脏获益。
  • 临床决策时可依据基线UACR评估卡格列净的绝对获益大小,UACR越高绝对获益越大。

局限性

  • 本研究为CREDENCE试验的二次分析,结果需在更广泛人群中验证。
  • UACR≥3000 mg/g亚组样本量较小(n=506),结果解释需谨慎。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND OBJECTIVES: The kidney protective effects of renin-angiotensin system inhibitors are greater in people with higher levels of albuminuria at treatment initiation. Whether this applies to sodium-glucose cotransporter 2 (SGLT2) inhibitors is uncertain, particularly in patients with a very high urine albumin-to-creatinine ratio (UACR; ≥3000 mg/g). We examined the association between baseline UACR and the effects of the SGLT2 inhibitor, canagliflozin, on efficacy and safety outcomes in the Canagliflozin and Renal Endpoints in Diabetes with Established Nephropathy Clinical Evaluation (CREDENCE) randomized controlled trial. DESIGN, SETTING, PARTICIPANTS, & MEASUREMENTS: The study enrolled 4401 participants with type 2 diabetes, an eGFR of 30 to <90 ml/min per 1.73 m2, and UACR of >300 to 5000 mg/g. Using Cox proportional hazards regression, we examined the relative and absolute effects of canagliflozin on kidney, cardiovascular, and safety outcomes according to a baseline UACR of ≤1000 mg/g (n=2348), >1000 to <3000 mg/g (n=1547), and ≥3000 mg/g (n=506). In addition, we examined the effects of canagliflozin on UACR itself, eGFR slope, and the intermediate outcomes of glycated hemoglobin, body weight, and systolic BP. RESULTS: Overall, higher UACR was associated with higher rates of kidney and cardiovascular events. Canagliflozin reduced efficacy outcomes for all UACR levels, with no evidence that relative benefits varied between levels. For example, canagliflozin reduced the primary composite outcome by 24% (hazard ratio [HR], 0.76; 95% confidence interval [95% CI], 0.56 to 1.04) in the lowest UACR subgroup, 28% (HR, 0.72; 95% CI, 0.56 to 0.93) in the UACR subgroup >1000 to <3000 mg/g, and 37% (HR, 0.63; 95% CI, 0.47 to 0.84) in the highest subgroup (Pheterogeneity=0.55). Absolute risk reductions for kidney outcomes were greater in participants with higher baseline albuminuria; the number of primary composite events prevented across ascending UACR categories were 17 (95% CI, 3 to 38), 45 (95% CI, 9 to 81), and 119 (95% CI, 35 to 202) per 1000 treated participants over 2.6 years (Pheterogeneity=0.02). Rates of kidney-related adverse events were lower with canagliflozin, with a greater relative reduction in higher UACR categories. CONCLUSIONS: Canagliflozin safely reduces kidney and cardiovascular events in people with type 2 diabetes and severely increased albuminuria. In this population, the relative kidney benefits were consistent over a range of albuminuria levels, with greatest absolute kidney benefit in those with an UACR ≥3000 mg/g. CLINICAL TRIAL REGISTRY NAME AND REGISTRATION NUMBER: ClinicalTrials.gov: CREDENCE, NCT02065791. PODCAST: This article contains a podcast at https://www.asn-online.org/media/podcast/CJASN/2021_02_22_CJN15260920_final.mp3.

来源:Clin J Am Soc Nephrol,查看原文。版权归原作者所有。

引用

  1. Jardine M, Zhou Z, Lambers Heerspink HJ, et al. Kidney, Cardiovascular, and Safety Outcomes of Canagliflozin according to Baseline Albuminuria: A CREDENCE Secondary Analysis. Clin J Am Soc Nephrol. 2021. PMID: 33619120. doi:10.2215/CJN.15260920

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。